Clinical evidence for thrombospondin-1 as a relevant suppressor of liver regeneration
To the Editor:
The most significant factor determining morbidity and mortality following hepatectomy is the ability of the remnant liver to regenerate. In this context, Hayashi et al. [1] recently reported on a previously unknown role of thrombospondin-1 (TSP-1) in liver regeneration (LR). During tissue remodeling, TSP-1 is released into the pericellular space to regulate cell survival and extracellular matrix remodeling [2] . A major TSP-1 function is the conversion of latent TGF-b 1 (transforming growth factor-beta 1) to its active form [3] . Based on a mouse model of partial hepatectomy, Hayashi et al. [1] demonstrated that TSP-1 was rapidly released in response to liver resection and triggered TGF-b 1 activation and signal transduction in hepatocytes as a mechanism to inhibit the proliferative hepatic response [4] [5] . Accordingly, knockdown of TSP-1 expression resulted in a significant reduction of TGF-b 1 signaling, which promoted the proliferation of hepatocytes and accelerated LR [1] . Thus, TSP-1 was proposed as an inhibitory element and a potential therapeutic target of LR. We are now able to present the first clinical data, which support the relevance of TSP-1 in LR based on a cohort of metastasized colorectal cancer (mCRC) patients undergoing hepatic resection of liver metastases. A total of 66 mCRC patients without preexisting liver disease were included. Blood was retrieved before surgery (pre OP) and on day 1 (POD1) or days 5-8 (POD5) after liver resection, and plasma was prepared with an optimized method [6] [7] . Samples were assayed by ELISA for human TSP-1 (R&D Systems, Minneapolis, MN, USA) and TGF-b 1 (eBioscience, San Diego, CA, USA). For statistical analysis, non-parametric tests (Mann-Whitney U test, Wilcoxon test and Spearman correlation) and the Fisher exact test were applied.
A significant increase in TSP-1 ( Fig. 1A ) and TGF-b 1 was observed on POD1 (p = 0.007 and p = 0.006, respectively), which dropped moderately until POD5 (p = 0.016 and p = 0.397). Circulating TSP-1 and TGF-b 1 showed a highly significant correlation (k = 0.736, p <0.001). To further investigate whether a high postoperative release of TSP-1 or TGF-b 1 was associated with delayed LR, we assessed the incidence of postoperative liver dysfunction (LD), based on the previously defined ''50-50 criteria'' [8] , with a prothrombin time (PT) <50% and a serum bilirubin (SB) level >50 lmol/L (>2.9 mg/dl). Our classification referred to measurements of any day within the first postoperative week to identify patients with delayed postoperative hepatic recovery. TSP-1 concentrations were significantly elevated ( Fig. 1B) in patients with LD (median TSP-1 for LD: 98.8 ng/ml; no LD: 44.6 ng/ml, p = 0.003). Comparably, circulating TGF-b 1 tended to be increased in individuals with LD (median TGF-b 1 for LD: 2266 pg/ml; no LD: 1726 pg/ml), but the difference was not statistically significant (p = 0.102). Of note, our analyses were restricted to total TGF-b 1 in patient blood since activated TGF-b 1 was below ELISA detec-tion limit. This may explain the lack of association between TGF-b 1 levels and postoperative LD.
To further characterize the potential of TSP-1 to predict postoperative LD, a ROC analysis was performed (Fig. 1C) , revealing a significant predictive value of circulating TSP-1 on POD1 (AUC: 0.870; p = 0.003). A cut-off level of 100 ng/ml TSP-1 on POD1 was deduced to determine the high-risk group for postoperative LD with 95% specificity. No statistically significant difference in age and sex distribution or the site of primary tumor, type of hepatic resection and preoperative liver function parameters was observed between the TSP-1 high individuals (>100 ng/ml TSP-1) and patients with lower circulating TSP-1 levels on POD1.
When biochemical markers of postoperative liver function were compared between these groups, the TSP-1 high patients showed a significant elevation in SB (Fig. 1D ) and c-glutamyltransferase (p <0.001; p = 0.011). Prothrombin time (Fig. 1E ) was found to be significantly decreased in TSP-1 high patients (p <0.001). aminotransferase levels was found in TSP-1 high patients but did not reach statistical significance (p = 0.125 and p = 0.092). We further assessed the clinical performance of TSP-1 high individuals in terms of morbidity and hospital stay. Only 4 patients suffered from severe morbidity of grade III, IV or V according to Dindo et al. [9] , which limits the conclusions of the statistical analysis. However, TSP-1 levels were significantly elevated in patients with severe complications (p = 0.016) and we found a substantial increase of postoperative severe morbidity from 4% to 33% in the TSP-1 high subgroup (p = 0.053). With respect to hospital stay, a highly significant correlation of TSP-1 levels on POD1 with days of postoperative hospitalization was observed (k = 0.488; p <0.001). In accordance, TSP-1 high patients required a doubled median hospitalization time of 16.5 days as compared to 8 days for the remaining patients to recover from hepatectomy (p = 0.011).
In conclusion, these are the first clinical data confirming that TSP-1 negatively correlates with liver regeneration in humans, which warrants validation in large-scale studies. TSP-1 may prove a helpful clinical marker to predict LD on the first postoperative day and to identify high-risk patients for potential complications and suitable interventions.
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